A new technology allows scientists to map the DNA-binding sites of transcription factors and other regulatory proteins that control gene activity, according to a study led by Weill Cornell Medicine and the New York Genome Center.
A clinical trial demonstrated that an all-oral drug combination for older patients with acute myeloid leukemia is an effective alternative to the current standard, which requires repeated hospital or office visits for intravenous treatment.
Weill Cornell Medicine received a five-year, $5 million grant from the National Cancer Institute to develop innovative support strategies for an understudied group of cancer patients: adolescents and young adults.
Targeting tumor-specific inflammatory processes in colorectal cancer could enhance the efficacy of some anticancer therapies and prevent drug resistance, Weill Cornell researchers have found.
